<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556450</url>
  </required_header>
  <id_info>
    <org_study_id>Homage</org_study_id>
    <nct_id>NCT02556450</nct_id>
  </id_info>
  <brief_title>Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure</brief_title>
  <acronym>Homage</acronym>
  <official_title>Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) &quot;HOMAGE&quot; Programme &quot; Heart OMics in AGing &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACS Biomarker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ACS Biomarker</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite advances in care, prognosis remains poor once overt Heart Failure (HF) has developed.
      Prevention is most efficient when directed toward patients at risk and when mechanistically
      targeted to patients most likely to respond. An increase in myocardial and possibly vascular
      collagen content (fibrosis) may be a major determinant of the transition to HF. In patients
      with hypertension and diabetes, two important risk-factors for HF, changes in blood markers
      of fibrosis occur before clinically overt HF develops. These markers are also related to
      prognosis.

      In the general population, Galectin-3 (Gal-3), a potential marker of fibrosis, is associated
      with cardiovascular (CV) risk factors, and predicts development of HF. In animal models,
      Gal-3 is a key mediator of aldosterone-induced CV and renal fibrosis and dysfunction.

      The investigators hypothesize that the mineralocorticoid receptor antagonist (MRA),
      spironolactone, may prevent HF by acting on extracellular matrix remodelling, especially in
      patients with active fibrogenesis, identified by high Gal-3 levels. The benefit/risk ratio of
      spironolactone might be superior in patients with a higher compared to lower plasma
      concentrations of Gal-3.

      Main objective is to investigate whether spironolactone can favourably alter extra-cellular
      matrix remodelling, assessed by changes in the fibrosis biomarker Procollagen Type III
      N-Terminal Peptide (PIIINP), in patients at increased risk of developing heart failure and
      whether this effect is greater in patients with increased plasma concentrations of Gal-3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that the mineralocorticoid receptor antagonist (MRA),
      spironolactone, may prevent HF by acting on extracellular matrix remodelling, especially in
      patients with active fibrogenesis, identified by high Gal-3 levels. The benefit/risk ratio of
      spironolactone might be superior in patients with a higher compared to lower plasma
      concentrations of Gal-3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in serum concentrations of PIIINP</measure>
    <time_frame>9 months</time_frame>
    <description>mmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in serum plasma levels of Biomarkers</measure>
    <time_frame>9 months</time_frame>
    <description>PICP (synthesis), ICTP (degradation) and GAL3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac remodelling 1</measure>
    <time_frame>9 months</time_frame>
    <description>NT-proBNP (ELISA, central Lab), from baseline to 9 months (Certified centers and central readings).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac remodelling 2</measure>
    <time_frame>9 months</time_frame>
    <description>Left Ventricular Mass (g/m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac remodelling 3</measure>
    <time_frame>9 months</time_frame>
    <description>Left Atrial Volume (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory performance during exercise</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Shuttle walk test: Distance walked in meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function</measure>
    <time_frame>screening, baseline, month1, month3, month 6, month 9</time_frame>
    <description>non-invasive technologies: BP lab Audicor system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure or AF</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of the clinical composite of development of heart failure or atrial fibrillation, non-fatal myocardial infarction or stroke or CV death from baseline to 9 months. The HOMAGE blinded clinical event committee will adjudicate all serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>screening, baseline, month1, month3, month 6, month 9</time_frame>
    <description>All adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>screening, baseline, month1, month3, month 6, month 9</time_frame>
    <description>decline in eGFR &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperkalemia</measure>
    <time_frame>screening, baseline, month1, month3, month 6, month 9</time_frame>
    <description>rise of serum potassium to &gt;5.5 mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">528</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Spironolacton Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolacton Sandoz given 25mg daily oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only background treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolacton</intervention_name>
    <description>Administration of Spironolacton 25 mg per day</description>
    <arm_group_label>Spironolacton Group</arm_group_label>
    <other_name>Spironolacton Sandoz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent will be obtained prior to any study procedure;

          -  Age &gt;60 years

          -  Clinical risk factors for developing heart failure, either:

               1. Coronary artery disease (h/o myocardial infarction, angioplasty or coronary
                  artery bypass) Or

               2. At least two of the following:

                    -  Diabetes Mellitus requiring Hypoglycaemic Pharmacotherapy

                    -  Receiving pharmacological treatment for Hypertension

                    -  Microalbuminuria

                    -  Abnormal ECG (left ventricular hypertrophy, QRS &gt;120msec, abnormal Q-waves)

          -  Biological risk: NT-pro-BNP values between 125 and 1,000 ng/L or BNP values between 35
             and 280 pg/ml (consistent with ESC guidelines indicating risk of HF but helping to
             rule out prevalent HF or atrial fibrillation which are associated with marked
             increases in NT-proBNP/BNP and should be investigated)

        Exclusion Criteria:

          -  Recent wound healing/inflammation:

          -  Surgical procedure, coronary, cerebral or peripheral vascular events or infection in
             the prior 3 months

          -  Cancer

          -  Autoimmune disease

          -  Hepatic Disease

          -  Pre-existing diagnosis of clinical HF

          -  Moderate/severe LV systolic ventricular dysfunction, i.e. LVEF &lt;45%

          -  Moderate or severe valve disease (investigators opinion)

          -  eGFR&lt; 30ml/min

          -  Serum potassium &gt;5.0 mmol/L

          -  Treatment with an MRA or a loop diuretic (furosemide, bumetanide, ethacrynic acid or
             torasemide) in the previous three months

          -  Potassium supplements or potassium-sparing diuretic at time of enrolment.

          -  Atrial fibrillation within one month prior to inclusion (AF lasting &lt;60 seconds on
             ambulatory ECG monitoring is permitted)

             •. History of hypersensitivity to spironolactone.

          -  Requiring treatment with prohibited medication according to SmPC with exception of ACE
             inhibitors or angiotensin receptor blockers

          -  Patients unable to give written informed consent.

          -  Participation in another interventional trial in the preceding month

          -  Ability to walk is, in the investigators opinion, clearly limited by joint disease or
             other locomotor problems rather than by cardiorespiratory fitness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Cleland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St, Michaels Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Margherita Hospital</name>
      <address>
        <city>Cortona</city>
        <zip>52044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02556450/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

